Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus LIQUAEMIN LOCK FLUSH.
EDOXABAN vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
60 mg orally once daily
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category C
Category C
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."